乳腺癌^(99m)Tc-MIBI显像与MRP、TOPO—Ⅱ表达的关系  

The study on relationship between ^(99m)Tc-MIBI scinigraphy of breast cancer and expression of MRP and TOPO-Ⅱ

作　　者：陈景伟[1] 马桃花 杨晓君[1] 余建军[3] 

机构地区：[1]宁夏银川市第一人民医院,宁夏银川750001 [2]宁夏同心县人民医院,宁夏同心751300 [3]宁夏医科大学附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2010年第8期690-692,共3页Ningxia Medical Journal

摘　　要：目的探讨乳腺癌对99m锝-甲氧基异丁基异腈(99mTc-MIBI)的摄取、滞留与多药耐药相关蛋白(MRP)、拓扑异构酶-Ⅱ(TOPO—Ⅱ)表达的关系。方法对60例乳腺癌患者进行99-Tc-MIBI乳腺显像:静脉注射显像剂99mTc-MIBI740MBq后20、120min分别行99mTc-MIBI乳腺显像,采用感性趣区(ROI)技术计算早期摄取比值(T/Ne)和延迟摄取比值(T/Nd)并根据公式RI%=(T/Nd—T/Ne)/T/Ne×100计算滞留率(RI%)。采用免疫组化法检测乳腺癌组织MRP、TOPO—Ⅱ表达水平,并与T/N比值和RI%进行相关性分析。结果在60例乳腺癌患者中99mTc-MIBI乳腺显像阳性者56例,阳性率为93.33%;对56例99mTc-MIBI乳腺显像阳性患者进行免疫组化检测MRP、TOPO—Ⅱ,表达阳性率分别为58.93%、67.86%。MRP、TOPO—Ⅱ表达阳性组和阴性组间T/Ne、T/Nd、RI%间比较均无统计学意义。结论 99mTc-MIBI乳腺显像的摄取、滞留均与乳腺癌组织MRP、TOPO—Ⅱ的表达无关。Objective To investigate the relationship between the degree of 99mTc-methoxyas/butylisoni-trile （ MIBI） uptake and expression of multidrug-resistant protein MRP,TOPO-Ⅱ in patients with breast cancer.Methods Sixty patients with untreated breast cancer were studied prospectively.After intravenous administration of 740MBq 99mTc-MIBI,anterior planar Scintigraphy was ac-quired at 20min and 120min after injection.Such indexes as early uptake radio,delay uptake radio and retention index （ RI% ） were calculated respectively.Immunohistochemical analysis was used to evaluate the expression of MRP and TOPO-Ⅱ.Results The positive rate of 99mTc-MIBI in the patient with breast cancer was 93.33% .The positive expression rates of MRP and TOPO-Ⅱ were respectively 58.93% and 67.86% （ P0.05） .Conclusions The study suggests that 99mTc-MIBI scintigraphy may not predict the MDR development associated with MRP,TOPO-Ⅱ expression in breast cancer.

关 键 词：乳腺癌 99m锝-甲氧基异丁基异腈 多药耐药蛋白 核素显像 

分 类 号：R737.9[医药卫生—肿瘤]